Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
OBJECTIVE: To evaluate the efficacy, pharmacokinetics, immunogenicity, and safety of multiple infusions of a chimeric monoclonal anti-tumor necrosis factor alpha antibody (cA2) (infliximab; Remicade, Centocor, Malvern, PA) given alone or in combination with low-dose methotrexate (MTX) in rheumatoid...
Prif Awduron: | Maini, R, Breedveld, F, Kalden, JR, Smolen, J, Davis, D, Macfarlane, J, Antoni, C, Leeb, B, Elliott, M, Woody, J, Schaible, T, Feldmann, M |
---|---|
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
1998
|
Eitemau Tebyg
-
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
gan: Elliott, M, et al.
Cyhoeddwyd: (1994) -
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
gan: Maini, R, et al.
Cyhoeddwyd: (1999) -
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
gan: Lipsky, P, et al.
Cyhoeddwyd: (2000) -
Infliximab and methotrexate in the treatment of rheumatoid arthritis
gan: Lipsky, P, et al.
Cyhoeddwyd: (2000) -
Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis.
gan: Paleolog, E, et al.
Cyhoeddwyd: (1996)